Concurrent Chaga's disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Therapeutics and Clinical Risk Management

Volumn 4, Issue 3, 2008, Pages 659-663

  Paniz Mondolfi, Alberto E ^a,b   Pérez Álvarez, Alexandra M ^a   Reyes Jaimes, Oscar ^a   Socorro, Gustavo ^a   Zerpa, Olga ^a   Slova, Denisa ^b   Concepción, Juan L ^c  

^a INSTITUTO DE BIOMEDICINA   (Venezuela)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Amiodarone; Chagas' disease; Chemotherapy; Leishmaniasis

Indexed keywords

AMIODARONE;

AGED; ANTIPROTOZOAL ACTIVITY; ARTICLE; CASE REPORT; CHAGAS DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART VENTRICLE ARRHYTHMIA; HOLTER MONITORING; HUMAN; LEISHMANIA BRAZILIENSIS; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; SKIN BIOPSY; SKIN LEISHMANIASIS; SKIN TEST;

EID: 47849091390     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bastrenta B, Mita N, Buitrago R, et al. 2003. Human mixed infections of Leishmania spp. And Leishmania-Trypanosoma cruzi in a sub Andean Bolivian area: Identification by polymerase chain reaction/ hybridization and isoenzyme. Mem Inst Oswaldo Cruz, 98:255-64.
2. Benaim G, Sanders JM, Garcia-Marchan Y, et al. 2006. Amiodarone has intrinsic anti-trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem, 49:892-99.
3. Convit J, Ulrich M, Fernandez CT, et al. 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans Roy Soc Trop Med Hyg, 87:444-8.
4. Convit J. 1996. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela. Clin Dermatol, 14:479-87.
5. Courchesne WE, Ozturk S. 2003. Amiodarone induces a caffeine-inhibited, MID-1-dependent rise in free cytoplasmic calcium in Saccharomyces cerevisiae. Mol Microbiol, 47:223-34.
6. Courchesne WE. 2002. Characterization of a novel, broad-based fungicidal activity for the antiarrhytmic drug amiodarone. J Pharmacol Exp Ther. 300:195-9.
7. Croft SL, Barrett MP, Urbina JA. 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol, 21:508-12.
8. Dias E, Laranja FS, Miranda A, et al. 1956. Chagas' disease; a clinical, epidemiologic, and pathologic study. Circulation, 14:1035-60.
9. Gupta SS, Ton VK, Beaudry V, et al. 2003. Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem, 278:28831-9.
10. Lawn SD, Armstrong M, Chilton D, et al. 2006. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg, 100:264-9.
11. Marin-Neto JA, Cunha-Neto E, Maciel BC, et al. 2007. Pathogenesis of chronic Chagas heart disease. Circulation, 115:1109-23.
12. Mendes DG, Lauria-Pires L, Nitz N, et al. 2007. Exposure to mixed asymptomatic infections with Trypanosoma cruzi, Leishmania braziliensis and Leishmania chagasi in the human population of the greater amazon. Trop Med Int Health, 12:629-36.
13. Murray HW, Berman JD, Davies CR, et al. 2005. Advances in leishmaniasis. Lancet, 366:1561-77.
14. Opie LH, Gersh BJ. 2005. Antiarrhytmic drugs and strategies. In: Drugs for the Heart. 6th edition. Philadelphia: Elsevier Inc., 218-74.
15. Schwartz E, Hatz C, Blum J. 2006. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis, 6:342-9.
16. Seear MD. 2000. Manual of tropical pediatrics. Cambridge: Cambridge University Press, Inc.
17. Silveira FT, Lainson R, Corbett CEP. 2004. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil-A review. 99:239-51.
18. Singh BN. 2006. Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep, 8:349-55.
19. Urbina JA, Docampo R. 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol, 19:495-501.